Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnlgs (NQ: ADVM )

13.32 USD +0.49 (+3.82%)
Official Closing Price Updated: 7:07 PM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 863,500
Open 12.89
Bid (Size) 12.40 (1)
Ask (Size) 13.59 (1)
Prev. Close 12.83
Today's Range 12.85 - 13.46
52wk Range 7.360 - 26.98
Shares Outstanding 62,271,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
From GlobeNewswire News Releases
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call 
From GlobeNewswire News Releases

Performance

YTD
+11.19%
+11.19%
1 Month
+7.85%
+7.85%
3 Month
-1.99%
-1.99%
6 Month
+9.18%
+9.18%
1 Year
+1.37%
+1.37%

More News

Read More
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
From GlobeNewswire News Releases
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
From GlobeNewswire News Releases
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy
From GlobeNewswire News Releases
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
From GlobeNewswire News Releases
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
From GlobeNewswire News Releases
Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Implied XBI Analyst Target Price: $205
Tags ETFs
From ETF Channel
Notable Insider Buys Of The Past Week: Affirm, HEICO, Vector Group, Biotechs And More
Tags OMI WOOF GABC
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.